Financing channel feed

TiGenix’s sec­ond stab at an IPO bags $36M for late-stage stem cell plans

9 years ago

Flag­ship takes on a pi­o­neer­ing new fund — and name — adding $285M to ad­vance its start­up mis­sion

9 years ago

New York gam­bles $1.15B in new funds and in­cen­tives in search of a biotech jack­pot

9 years ago

Sec­tion 32: Ex-Google ven­ture chief Maris pur­sues in­die role with $230M biotech fund

9 years ago

Bio­gen vet Adam Kop­pel is rais­ing cash for a new life sci­ences fund at Bain Cap­i­tal

9 years ago

GSK vet Ja­son Gard­ner takes the helm of Ma­gen­ta, emerg­ing from stealth with a $48.5M round

9 years ago
Startups

Syn­cona, CRUK and BAC­IT join forces to cre­ate a $1.2B biotech in­vest­ment pow­er­house

9 years ago

In­flu­en­tial Third Rock Ven­tures marks a decade of high-pro­file wins and loss­es with record $616M Fund IV

9 years ago

Turn­ing phar­ma castoffs in­to an in­stant for­tune, Vivek Ra­maswamy’s My­ovant bags a $218M IPO

9 years ago

Gene edit­ing los­es its siz­zle. CRISPR Ther­a­peu­tics IPO de­buts be­neath the range

9 years ago

Nan­cy Stagliano bags an­oth­er $45M for True North’s rare dis­ease R&D

9 years ago
Startups

Armed an­ti­body play­er ADC lands a $105M mega-round to back pipeline con­struc­tion

9 years ago
Startups

Sofinno­va bags $650M for a ded­i­cat­ed biotech fund

9 years ago

Biotechs grabbed $1.83B in VC cash in Q3. Still fast but a lit­tle less fu­ri­ous

9 years ago

Azur­Rx clips its IPO price, but man­ages to get the job done

9 years ago

Helsinn sets up a bou­tique in­vest­ment fund with a rov­ing eye for on­col­o­gy up­starts

9 years ago

Reuters probe spot­lights a con­flict of in­ter­est be­tween biotech in­vestor F-Prime and gi­ant Fi­deli­ty

9 years ago

UK start­up tack­les hot neoanti­gen field in can­cer drugs

9 years ago
Startups

Presto! Wall Street ma­gi­cian Vivek Ra­maswamy has an­oth­er in­stant biotech IPO to sell you

9 years ago
People

Alzheimer’s play­er AC Im­mune taps IPO for $58M raise, sees shares soar

9 years ago

The next check­points? Im­muno-on­col­o­gy up­start looks to find new ways to un­leash T cells

9 years ago
Startups

Out of lim­bo, Sarep­ta is rais­ing $225M and tak­ing bids on a pri­or­i­ty vouch­er as it revs up mar­ket­ing

9 years ago
Pharma

Biotech uni­corn Mod­er­na gam­bles $110M on a ground­break­ing mR­NA man­u­fac­tur­ing fa­cil­i­ty, blue­prints plant #2

9 years ago
R&D

Third Rock ramps up a $57M up­start fo­cus­ing on pro­teins in mo­tion

9 years ago
Startups
First page Previous page 142143144145146 Next page Last page
A service from the Financial Times